

## SAPPHIRE Study expands with inclusion of Ascension

Four high quality U.S. systems confirmed for SAPPHIRE Study - commencing early 2026

**PERTH, Australia, 13 November 2025:** Artrya Limited (ASX: AYA) (**Artrya** or the **Company**), a medical technology company commercialising its Salix® AI-powered cloud platform, for the near real time, point of care assessment and management of coronary artery disease, is pleased to announce that Ascension, one of the largest non-profit and Catholic health systems in the U.S., has agreed to participate in the U.S. multi-centre clinical SAPPHIRE Study, subject to final documentation and their ethics approval.

### Highlights

- **SAPPHIRE Study expanded into fourth major U.S. healthcare system, with Ascension confirming their participation in the Study subject to contracting and their ethics approval**
- **Ascension based in St Louis, is the sixth largest<sup>1</sup> non-profit systems in the U.S., and provides healthcare services across 16 states in the U.S. and the District of Columbia - operating 94 hospitals and with partnerships in 27 additional hospitals**
- **The Ascension Cardiovascular Research Institute provides advanced research in cardiovascular care – part of Ascension Clinical Research Institute which has nearly 3,000 active or approved studies at any time**
- **SAPPHIRE Study on track for early 2026 to assess how Salix® and Artrya's novel Plaque Dispersion Score can detect coronary artery disease earlier and more effectively**

#### **John Konstantopoulos, Co-Founder and CEO of Artrya commented:**

*"We are delighted to have Ascension join as a collaborator in the SAPPHIRE Study. Ascension's national scale and commitment to advancing innovative cardiovascular care will further strengthen the reach of our study. Through Ascension Cardiovascular Research Institute, they provide us deep research and prolific clinical trial capabilities.*

*With our fourth major U.S. healthcare system now secured, we are well on our way to reaching our target of 6 to 8 participants in the SAPPHIRE Study. We are accelerating our activities with the remaining centres we expect to be involved and also finalising our Study protocols as we prepare to launch in early 2026."*

#### **Andy Zurick III, MD, FACC, Preventive & Imaging Cardiologist, Medical Director of Cardiac CT and MRI at Ascension St Thomas Heart said:**

*"At Ascension, we are committed to new and innovative technologies to improve treatment outcomes for our patients. The SAPPHIRE Study provides an opportunity to explore new frontiers in cardiovascular care. By applying Artrya's advanced AI solutions, particularly the Plaque Dispersion Score, we aim to improve our understanding of coronary risk at the individual level. Ascension is committed to leveraging innovation to improve patient outcomes, and we are pleased to partner with Artrya on this important initiative."*

## Ascension becomes fourth SAPPHIRE Study participant– on track to launch in 2026

The addition of Ascension provides another very large U.S. hospital system with deep research and clinical trial capabilities to the SAPPHIRE Study, alongside Mass General Brigham, Piedmont Healthcare and Huntsville Hospital Heart Center. SAPPHIRE is a retrospective, multicentre, real-world study which will evaluate the clinical and prognostic value of Artrya's Salix® Plaque Analysis and its proprietary Plaque Dispersion Score (**PDS**), aiming to improve

<sup>1</sup> <https://www.definitivehc.com/blog/top-10-largest-health-systems>

identification of patients at elevated risk of cardiovascular events. This Study will also include a strong focus on improving care for women, 64%<sup>2</sup> of whom who die from coronary artery disease show no prior symptoms.

Ascension, based in St. Louis, Missouri, are nationally recognised for their leadership in heart and vascular services through the St. Vincent Cardiovascular Research Institute, a centre of excellence known for clinical innovation and integrated cardiovascular care that has a long-standing commitment to advancing heart and vascular care through clinical research. With more than 50 active trials currently underway and new studies commencing regularly, the Institute is recognised as a leading centre for cardiovascular innovation.

Ascension is a one of the largest non-profit and faith-based health systems in the United States. Operating across 16 U.S. states and the District of Columbia, Ascension's network is approximately 99,000 associates, 23,000 aligned providers, 94 hospitals, as well as ownership interests in 27 additional hospitals through partnerships<sup>3</sup>.

- Ends -

This ASX Announcement is authorised for release by the Board of Artrya Limited.

### About Artrya

Artrya Limited (ASX:AYA) is an Australian medical technology company developing AI-powered solutions to improve the detection and management of coronary artery disease. Its proprietary software analyses coronary CT scans to identify key biomarkers of heart disease, supporting clinicians in diagnosing patients more accurately and efficiently. Artrya's mission is to advance cardiac care through innovative technology, with regulatory and commercial activities underway across key international markets.

For more information visit [www.artrya.com](http://www.artrya.com) or follow us on LinkedIn at [www.linkedin.com/company/artrya](http://www.linkedin.com/company/artrya)

### Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates and Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of Artrya. The Estimates and Projections are based on information available to Artrya as at the date of the Announcement, are based upon management's current expectations, estimates, projections, assumptions and beliefs in regards to future events in respect to Artrya's business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of Artrya and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by Artrya in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. Artrya takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

### For more information:

<sup>2</sup> Comprehensive plaque assessment by coronary CT angiography. Nat Rev Cardiol 11, 390–402 (2014)

<sup>3</sup> <https://about.ascension.org/about-us>

## Corporate Enquiries

### John Konstantopoulos

Co-Founder and Chief Executive Officer

Tel: +61 8 6478 7816

Email: [contact@artrya.com](mailto:contact@artrya.com)

## Investor & Media Enquiries

### David Allen or John Granger

Hawkesbury Partners

Tel: +61 499 100 038 or +61 410 577 155

Email: [investors@artrya.com](mailto:investors@artrya.com)

For personal use only